Neuland Laboratories Limited has informed the Exchange about Transcript
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Neuland Laboratories reported a weak Q4 FY25 with total income of INR 335.8 crores, down 14% year-on-year, and EBITDA margin of 17.3% versus 28.7% in Q4 FY24. For full year FY25, revenue dipped 4.7% to INR 1,497.3 crores, and EBITDA (excluding exceptional items) fell to INR 342.8 crores from INR 474.5 crores in FY24. The company generated INR 111 crores of free cash flow, repaid INR 39.4 crores of term loans, and ended FY25 with a net cash position of INR 29 crores. Management said FY25 was a year of consolidation and that growth should resume in FY26 on the FY24 base, driven by the newly capitalized Unit 3 production block, a second CMS molecule commercialization expected in FY26, and a healthy pipeline of 97 projects (up from 81 in FY22). The peptide business is progressing, with the first US DMF filed for Difelikefalin, and management reiterated confidence in the 20–25% three-year revenue CAGR target.
Short-term, the stock may stay under pressure as FY25 numbers were significantly below FY24 levels and management declined to give specific quarterly or margin guidance, frustrating investors. However, the net cash balance sheet, capex already done, and confirmed visibility into FY26 growth (new molecule, Unit 3 ramp-up, peptide platform) provide a constructive medium-term setup for shareholders willing to look past the weak year.